Description

KENATROY 40 MG INJ 1ML

Indications

KENATROY 40 MG INJ 1ML is primarily indicated for the treatment of various conditions related to vitamin K deficiency. It is commonly utilized in patients who are at risk of bleeding due to anticoagulant therapy or other medical conditions that impair vitamin K absorption. This injectable formulation is also indicated for the management of certain coagulation disorders, including those associated with liver disease or malabsorption syndromes.

Mechanism of Action

KENATROY contains vitamin K1 (phytomenadione), which plays a crucial role in the synthesis of clotting factors II (prothrombin), VII, IX, and X in the liver. These factors are essential for normal blood coagulation. Vitamin K is a cofactor for the enzyme gamma-glutamyl carboxylase, which catalyzes the carboxylation of specific glutamic acid residues on these clotting factors. This post-translational modification is necessary for their activity and stability. By replenishing vitamin K levels, KENATROY effectively restores the synthesis of functional clotting factors, thereby reducing the risk of bleeding in patients.

Pharmacological Properties

KENATROY is administered via intramuscular or intravenous injection. The pharmacokinetics of vitamin K1 involve rapid absorption and distribution in the body, with peak plasma concentrations typically occurring within a few hours post-administration. The half-life of vitamin K1 is approximately 1 to 3 hours, and it is primarily metabolized in the liver. Excretion occurs mainly through bile, with a small amount eliminated in urine. The pharmacological effects of KENATROY can be observed within 12 to 24 hours after administration, depending on the clinical condition being treated.

Contraindications

KENATROY should not be administered to patients with a known hypersensitivity to vitamin K1 or any of the excipients contained in the formulation. Additionally, it is contraindicated in individuals who are experiencing severe liver disease, as the impaired synthesis of clotting factors may not be adequately corrected with vitamin K administration. Caution should also be exercised in patients with a history of anaphylactic reactions to vitamin K.

Side Effects

While KENATROY is generally well tolerated, some patients may experience side effects. Commonly reported adverse reactions include local reactions at the injection site, such as pain, swelling, or redness. Rarely, systemic allergic reactions may occur, including rash, itching, or anaphylaxis. Other potential side effects may include gastrointestinal disturbances, such as nausea or vomiting. It is essential for healthcare providers to monitor patients for any adverse effects following administration of KENATROY.

Dosage and Administration

The dosage of KENATROY varies depending on the indication and the severity of vitamin K deficiency. For adults, the typical initial dose may range from 10 to 20 mg, administered as a single injection. In cases of severe bleeding or high INR levels, higher doses may be required, and repeat dosing may be necessary based on clinical response and laboratory monitoring. For pediatric patients, the dosage should be determined by a healthcare professional, taking into consideration the child’s weight and clinical condition. KENATROY should be administered under the supervision of a qualified healthcare provider to ensure proper dosing and monitoring.

Interactions

KENATROY may interact with various medications, particularly anticoagulants such as warfarin. The administration of vitamin K can reduce the effectiveness of warfarin therapy, leading to an increased risk of thromboembolic events. Therefore, it is crucial to monitor INR levels closely when initiating or adjusting vitamin K therapy in patients receiving anticoagulants. Other medications that may interact with KENATROY include certain antibiotics, cholestyramine, and orlistat, which can impair vitamin K absorption. A thorough medication review should be conducted to identify potential interactions before initiating treatment with KENATROY.

Precautions

Prior to administration of KENATROY, healthcare providers should assess the patient’s medical history, including any history of liver disease, allergies, or concurrent medications. It is important to monitor coagulation parameters, such as prothrombin time (PT) and INR, to evaluate the effectiveness of treatment and adjust dosages accordingly. Patients with a history of hypersensitivity reactions to vitamin K should be closely monitored during administration. Pregnant and breastfeeding women should use KENATROY only if clearly needed and under the guidance of a healthcare professional, as the safety of vitamin K in these populations has not been fully established.

Clinical Studies

Clinical studies have demonstrated the efficacy of KENATROY in reversing the effects of vitamin K antagonists and managing vitamin K deficiency-related bleeding. Research has shown that administration of vitamin K1 significantly reduces prothrombin time and improves coagulation status in patients receiving anticoagulant therapy. Additionally, studies have indicated that KENATROY is effective in treating vitamin K deficiency due to malabsorption syndromes or liver disease. The rapid onset of action and favorable safety profile make KENATROY a valuable therapeutic option in these clinical scenarios.

Conclusion

KENATROY 40 MG INJ 1ML is an essential therapeutic agent for the management of vitamin K deficiency and related coagulation disorders. Its mechanism of action, pharmacological properties, and clinical efficacy make it a critical component of treatment protocols for patients at risk of bleeding. Healthcare providers must be aware of the potential side effects, contraindications, and drug interactions associated with KENATROY to ensure safe and effective use. Ongoing monitoring and individualized dosing are paramount to achieving optimal therapeutic outcomes.